Open AccessPrognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer
Author(s) -
Gökhan Özyiğit,
Pervin Hürmüz,
Deniz Yüce,
Fadıl Akyol
Publication year - 2019
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v10.i8.283
Subject(s) - medicine , testosterone (patch) , prostate cancer , urology , androgen deprivation therapy , radiation therapy , androgen , castration , prostate , cancer , oncology , nuclear medicine , hormone
Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment (ADT) in metastatic prostate cancer (PC).